{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:49:07Z","timestamp":1790401747774,"version":"4.1.0"},"reference-count":21,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Mental health (MH) polypharmacy, defined as prescribing multiple mental health medications for the same condition, presents significant challenges in clinical practice. With varying prevalence rates and an increasing trend, particularly in the UK, this deprescribing prospective quality improvement project aimed to address the complexities and risks associated with MH polypharmacy. Patients and Methods: A large primary care centre in London was selected for this project. Electronic records of 667 patients (non-coded in mental health lists) were analysed as a result of the absence of a Systematised Nomenclature of Medicine Clinical Terms (SNOMED CT) for mental health. Seventy-two non-coded patients exhibiting \u201csame-class\u201d as well as \u201cadjunctive\u201d and \u201caugmentation\u201d polypharmacy were identified. Their demographic and health data, including MH diagnoses, physical status, and lifestyle habits, were evaluated. This deprescribing prospective project included 68 patients and employed a model inspired by the Plan\u2013Do\u2013Study\u2013Act (PDSA) cycle, focusing on reducing psychotropic, adjunctive, and augmentative medications while monitoring mental health control through face-to-face consultations using the Patient Health Questionnaire-9 (PHQ-9) and Generalised Anxiety Disorder Assessment-7 (GAD-7) scores, alongside physical health parameters. Results: The project revealed a significant decrease in the average number of psychotropic and adjunct medications from initial consultations to the end of the 18-month period. Additionally, a marked reduction in reported side effects and drug interactions was observed. Improvements in mental health control, as evidenced by PHQ-9 and GAD-7 scores, were noted. Physical health parameters, including BMI, blood pressure, heart rate, HbA1c, and cholesterol levels, also showed significant improvements. Educational initiatives for patients and clinicians were successfully implemented, contributing to these positive outcomes. Discussion: The project faced challenges like balancing medication reduction with mental health stability, patient apprehension, and the absence of standardised protocols. However, the successful reduction in medication numbers and the improvement in health outcomes highlight the effectiveness of the model. This project underscores the necessity of a tailored approach to MH polypharmacy, emphasising continuous education, clinical titration, and adherence to guidelines. Future research is needed to develop clear guidelines for medication combination in mental health care and to understand the long-term effects of polypharmacy in mental health populations. Conclusions: This project demonstrates the potential for significant improvements in the management of MH polypharmacy. By carefully managing medication reductions and employing a comprehensive care approach, including patient education and clinician training, the project achieved improvements in both mental and physical health outcomes. These findings suggest a promising direction for future practices in MH polypharmacy management.<\/jats:p>","DOI":"10.3390\/jcm13040958","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T11:03:14Z","timestamp":1707303794000},"page":"958","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Mental Health Polypharmacy in \u201cNon-Coded\u201d Primary Care Patients: The Effect of Deprescribing"],"prefix":"10.3390","volume":"13","author":[{"given":"Waseem","family":"Jerjes","sequence":"first","affiliation":[{"name":"Research and Development Unit, Hammersmith and Fulham Primary Care Network, Richford Street, London W6 7HY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6247-8398","authenticated-orcid":false,"given":"Daniele","family":"Ramsay","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Imperial College London, London SW7 2DD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5768-2300","authenticated-orcid":false,"given":"Harvey","family":"Stevenson","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Imperial College London, London SW7 2DD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Lalji","sequence":"additional","affiliation":[{"name":"Research and Development Unit, Hammersmith and Fulham Primary Care Network, Richford Street, London W6 7HY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"De Las Cuevas, C., and Sanz, E. (2004). Polypharmacy in psychiatric practice in the Canary Islands. BMC Psychiatry, 4.","DOI":"10.1186\/1471-244X-4-18"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/acps.12906","article-title":"Long-term antipsychotic polypharmacy prescribing in secondary mental health care and the risk of mortality","volume":"138","author":"Kadra","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/0973-1229.104497","article-title":"Polypharmacy in Psychiatry: A Review","volume":"11","author":"Kukreja","year":"2013","journal-title":"Mens Sana Monogr."},{"key":"ref_4","unstructured":"Medical Directors Council and State Medicaid Directors (2001). Technical Report on Psychiatric Polypharmacy, National Association of State Mental Health Program Directors."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20451253211000610","article-title":"Defining polypharmacy: In search of a more comprehensive determination method applied in a tertiary psychiatric hospital","volume":"11","author":"Govaerts","year":"2021","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3109\/08039488.2015.1127996","article-title":"Potentially inappropriate prescriptions in patients admitted to a psychiatric hospital","volume":"70","author":"Soerensen","year":"2016","journal-title":"Nord. J. Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4103\/2229-3485.148820","article-title":"Assessment of drug-related problems in depressive patients","volume":"6","author":"Mateti","year":"2015","journal-title":"Perspect. Clin. Res."},{"key":"ref_8","unstructured":"NHS Business Services Authority (2023, December 30). Medicines Used in Mental Health\u2014England. July 2023. Available online: https:\/\/www.nhsbsa.nhs.uk\/statistical-collections\/medicines-used-mental-health-england\/medicines-used-mental-health-england-201516-202223."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"J\u00f8nsson, A.B.R., Martiny, F.H.J., S\u00f8ndergaard, M.K., Brodersen, J.B., Due, T.D., Nielsen, M.H., Bakkedal, C., Bardram, J.E., Bissenbakker, K., and Christensen, I. (2023). Introducing extended consultations for patients with severe mental illness in general practice: Results from the SOFIA feasibility study. BMC Prim. Care, 24.","DOI":"10.1186\/s12875-023-02152-z"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJMcp1712493","article-title":"Depression in the Primary Care Setting","volume":"380","author":"Park","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1176\/ps.2009.60.9.1167","article-title":"Datapoints: Psychotropic drug prescriptions by medical specialty","volume":"60","author":"Mark","year":"2009","journal-title":"Psychiatr. Serv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jad.2019.04.018","article-title":"Psychotropic polypharmacy reconsidered: Between-class polypharmacy in the context of multimorbidity in the treatment of depressive disorders","volume":"252","author":"Rhee","year":"2019","journal-title":"J. Affect. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/jir.12391","article-title":"Prevalence, patterns and factors associated with psychotropic use in older adults with intellectual disabilities in Ireland","volume":"61","author":"Peklar","year":"2017","journal-title":"J. Intellect. Disabil. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1017\/S1041610220004032","article-title":"Prevalence of psychotropic polypharmacy in nursing home residents with dementia: A meta-analysis","volume":"33","author":"Jester","year":"2021","journal-title":"Int. Psychogeriatr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"644741","DOI":"10.3389\/fpsyt.2021.644741","article-title":"Psychotropic Polypharmacy in the US Pediatric Population: A Methodologic Critique and Commentary","volume":"12","author":"Zito","year":"2021","journal-title":"Front. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Uematsu, T., Tomita, T., Obara, R., Gonai, T., Hattori, K., Aonuma, T., Usui, K., Tanifuji, H., Ishizawa, F., and Ishii, H. (2023). Reducing the use of psychotropics in a convalescent rehabilitation ward. Neuropsychopharmacol. Rep.","DOI":"10.1002\/npr2.12388"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/JCP.0000000000001681","article-title":"Polypharmacy Among Patients with Major Depressive Disorder and Co-occurring Substance Use Disorders in a Psychiatric Hospital Setting: Prevalence and Risk Factors","volume":"43","author":"Benz","year":"2023","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.genhosppsych.2023.03.009","article-title":"Concurrent use of polypharmacy and potentially inappropriate medications with antidepressants in older adults: A nationwide descriptive study in Denmark during 2015\u20132019","volume":"82","author":"Mortensen","year":"2023","journal-title":"Gen. Hosp. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jsps.2022.12.004","article-title":"Potential drug-drug interactions in outpatients with depression of a psychiatry department","volume":"31","author":"Chen","year":"2023","journal-title":"Saudi Pharm. J."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Liu, Y., Yang, M., Ding, Y., Wang, H., Zhang, H., Wang, D., Zhuang, T., Ji, M., Cui, Y., and Wang, H. (2022). Clinical significance of potential drug-drug interactions in older adults with psychiatric disorders: A retrospective study. BMC Psychiatry, 22.","DOI":"10.1186\/s12888-022-04207-4"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1192\/bjp.2022.160","article-title":"Association between polypharmacy and depression relapse in individuals with comorbid depression and type 2 diabetes: A UK electronic health record study","volume":"222","author":"Jeffery","year":"2023","journal-title":"Br. J. Psychiatry"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/4\/958\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:56:39Z","timestamp":1760104599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/4\/958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["jcm13040958"],"URL":"https:\/\/doi.org\/10.3390\/jcm13040958","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]}}}